Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tergynan is a fixed-dose combination vaginal tablet designed for the local treatment of various forms of vaginitis, including bacterial, fungal, and parasitic infections. It contains four active ingredients: ternidazole, a nitroimidazole derivative with potent antiprotozoal and antibacterial activity against anaerobic organisms like *Trichomonas vaginalis*; neomycin sulfate, a broad-spectrum aminoglycoside antibiotic that inhibits bacterial protein synthesis; nystatin, a polyene antifungal effective against *Candida* species; and prednisolone, a corticosteroid that provides anti-inflammatory and antipruritic effects to relieve local irritation. This multi-modal approach allows for the effective management of mixed vaginal infections and provides rapid symptomatic relief. It was originally developed by Laboratoires Bouchara-Recordati and is widely used in several regions for gynecological infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ternidazole + neomycin + nystatin + prednisolone.